Is Glenmark Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glenmark Pharmaceuticals Ltd is a average quality company .

Is Glenmark Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Glenmark Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Glenmark Pharmaceuticals share price return in the past 10 years?

Glenmark Pharmaceuticals Ltd share price has appreciated 8.8% annually (CAGR) over the past ten years.

Is Glenmark Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Glenmark Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Glenmark Pharmaceuticals?

The latest standalone P/E ratio of Glenmark Pharmaceuticals as of 25-Oct-2024 is 8.78.

What is the P/B ratio of Glenmark Pharmaceuticals?

The latest standalone P/B ratio of Glenmark Pharmaceuticals as of 25-Oct-2024 is 2.00.

What is the 52-week high and low of Glenmark Pharmaceuticals?

The 52-week high of Glenmark Pharmaceuticals is Rs. 1830.05 and the 52-week low is Rs. 702.05.

Glenmark Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Glenmark Pharmaceuticals
Brand: Glenmark Pharmaceuticals

BSE: 532296 | NSE: GLENMARK | Pharmaceuticals & Drugs | Mid Cap

Place order

Glenmark Pharma Share Price

₹1,662.60 -10.60 -0.63%
as on 25-Oct'24 15:22

10 Year X-Ray of Glenmark Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	12.4%	18.5%	20.5%	14.8%	16.5%	14%	15.3%	14.2%	4.4%	4.9%	-
Value Creation Index ⓘ	-0.1	0.7	0.8	0.1	0.2	0.0	0.1	0.1	-0.7	-0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	6,681	7,562	9,079	9,074	9,865	10,641	10,944	12,305	11,583	11,813	11,860
Sales YoY Gr.	-	13.2%	20.1%	-0.1%	8.7%	7.9%	2.9%	12.4%	-5.9%	2%	-
Adj EPS ⓘ	12.6	26.7	43	26.8	24.2	23.3	35.1	37.8	7.8	-45	-46.5
YoY Gr.	-	113%	60.7%	-37.6%	-9.7%	-3.8%	50.8%	7.7%	-79.4%	-677.4%	-
BVPS (₹) ⓘ	65.7	128.6	159.2	182.6	198.3	214.7	249.6	321.5	335.1	277.5	289.5
Adj Net Profit ⓘ	341	754	1,212	757	683	657	991	1,067	220	-1,269	-1,311
Cash Flow from Ops. ⓘ	482	345	657	1,648	1,324	1,392	1,131	1,109	625	-265	-
Debt/CF from Ops. ⓘ	7.9	11.6	7.2	2.8	3.4	3.5	4.1	3.3	7	-3.7	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6.5%	3.7%	2.6%	2%
Adj EPS ⓘ	-215.2%	-213.2%	-208.6%	-677.4%
BVPSⓘ	17.4%	7%	3.6%	-17.2%
Share Price	8.8%	39.7%	48.9%	123.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	14.3	27.9	29.9	15.7	12.7	11.3	15.1	13.2	2.4	-14.7	-16.4
Op. Profit Mgn % ⓘ	18.2	19.2	23.2	17.8	16.1	16	19.7	18.9	14.1	10.1	11.4
Net Profit Mgn % ⓘ	5.1	10	13.4	8.3	6.9	6.2	9.1	9.1	2.6	-10.2	-11.1
Debt to Equity ⓘ	2.1	1.1	1.1	0.9	0.8	0.8	0.7	0.4	0.5	0.1	-
Working Cap Days ⓘ	244	242	219	236	217	201	88	88	94	88	117
Cash Conv. Cycle ⓘ	77	60	69	82	66	56	-28	-21	-4	-14	36

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 2.58%

Sales growth is not so good in last 4 quarters at -1.06%

Latest Financials - Glenmark Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	189.6	-46.5
TTM Sales (₹ Cr.)	7,849	11,860
BVPS (₹.) ⓘ	830	289.5
Reserves (₹ Cr.) ⓘ	23,394	8,142
P/BV ⓘ	2.00	5.75
PE ⓘ	8.78	0.00

From the Market
52 Week Low / High (₹)	702.05 / 1830.05
All Time Low / High (₹)	1.89 / 1830.05
Market Cap (₹ Cr.)	46,949
Equity (₹ Cr.)	28.2
Face Value (₹)	1
Industry PE ⓘ	46.2

Management X-Ray of Glenmark Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Glenmark Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Glenmark Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	6,681	7,562	9,079	9,074	9,865	10,641	10,944	12,305	11,583	11,813
Operating Expenses ⓘ	5,467	6,125	7,043	7,459	8,280	8,943	8,860	9,985	9,948	10,618
Manufacturing Costs	927	624	674	786	890	843	803	985	745	937
Material Costs	1,538	2,247	2,552	2,963	3,284	3,624	3,620	4,312	4,204	4,352
Employee Cost	1,213	1,378	1,641	1,872	2,056	2,255	2,344	2,447	2,601	2,868
Other Costs ⓘ	1,788	1,876	2,176	1,838	2,049	2,221	2,092	2,240	2,398	2,460
Operating Profit ⓘ	1,214	1,437	2,037	1,615	1,586	1,698	2,084	2,320	1,635	1,195
Operating Profit Margin (%)	18.2%	19.0%	22.4%	17.8%	16.1%	16.0%	19.0%	18.9%	14.1%	10.1%
Other Income ⓘ	7	20	37	91	208	160	50	167	289	840
Interest ⓘ	190	179	237	286	335	377	353	298	349	516
Depreciation ⓘ	300	234	264	302	326	417	444	487	569	582
Exceptional Items ⓘ	-187	0	-81	0	167	33	45	-261	-766	-901
Profit Before Tax ⓘ	544	1,044	1,491	1,119	1,301	1,096	1,382	1,441	240	36
Tax ⓘ	334	301	383	315	376	320	412	448	329	1,867
Profit After Tax	209	743	1,109	804	925	776	970	994	-90	-1,831
PAT Margin (%)	3.1%	9.8%	12.2%	8.9%	9.4%	7.3%	8.9%	8.1%	-0.8%	-15.5%
Adjusted EPS (₹)	7.7	26.3	39.3	28.5	32.8	27.5	34.4	33.4	10.5	-53.2
Dividend Payout Ratio (%)	26%	8%	5%	7%	6%	9%	7%	7%	24%	-5%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,783	3,628	4,491	5,153	5,595	6,057	7,043	9,070	9,456	7,830
Share Capital ⓘ	27	28	28	28	28	28	28	28	28	28
Reserves ⓘ	1,756	3,600	4,463	5,125	5,566	6,029	7,015	9,042	9,428	7,801
Minority Interest	-0	-0	-0	-0	-0	-0	-0	351	365	-0
Debt	2,922	3,275	4,724	4,437	3,877	4,486	4,402	2,942	4,202	833
Long Term Debt	2,574	2,487	4,536	4,142	3,574	4,043	3,889	2,572	3,852	0
Short Term Debt	348	787	187	295	303	443	513	370	350	833
Trade Payables	1,948	1,941	1,743	1,870	2,221	2,126	2,238	2,289	2,000	2,536
Others Liabilities ⓘ	1,656	285	-505	-184	214	561	387	745	1,542	2,110
Total Liabilities ⓘ	8,309	9,128	10,453	11,275	11,906	13,229	14,069	15,397	17,566	13,309
Fixed Assets
Gross Block	3,495	4,301	4,770	5,368	6,527	8,270	8,732	10,213	10,360	9,620
Accumulated Depreciation	1,480	1,707	2,015	2,338	2,857	3,241	3,603	4,326	4,938	5,409
Net Fixed Assetsⓘ	2,015	2,594	2,755	3,030	3,670	5,029	5,129	5,887	5,422	4,210
CWIP ⓘ	477	543	708	1,122	1,399	1,222	1,382	1,010	1,190	662
Investmentsⓘ	17	17	16	15	30	25	25	50	45	790
Inventories	1,269	1,568	2,139	2,031	2,252	2,136	2,277	2,500	2,374	2,513
Trade Receivables	2,512	2,493	2,404	2,332	2,195	2,409	2,572	3,101	3,665	1,858
Cash Equivalents	776	857	1,058	1,235	938	1,111	1,139	1,412	1,160	1,659
Others Assetsⓘ	1,243	1,057	1,373	1,512	1,423	1,298	1,546	1,438	3,711	1,616
Total Assets ⓘ	8,309	9,128	10,453	11,275	11,906	13,229	14,069	15,397	17,566	13,309

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	482	345	657	1,648	1,324	1,392	1,131	1,109	625	-265
PBT ⓘ	544	1,044	1,491	1,119	1,301	1,096	1,382	1,441	868	569
Adjustment ⓘ	523	391	727	571	330	636	645	787	1,472	1,010
Changes in Working Capital ⓘ	-267	-612	-862	309	136	127	-386	-561	-1074	-797
Tax Paid ⓘ	-318	-478	-699	-352	-443	-467	-510	-558	-641	-1,047
Cash Flow From Investing Activity ⓘ	-540	-880	-712	-1,013	-699	-784	-675	-333	-528	4,561
Capex	-538	-889	-733	-1,023	-610	-775	-675	-358	-551	-896
Net Investments	0	0	0	0	-15	5	0	-10	-1	7
Others ⓘ	-2	8	21	9	-74	-13	0	35	23	5,450
Cash Flow From Financing Activityⓘ	199	699	543	-468	-739	-445	-442	-520	-77	-3,906
Net Proceeds from Shares ⓘ	2	935	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	478	-441	1,400	-290	-381	-116	-67	-889	650	-3,649
Interest Paid ⓘ	-179	-180	-184	-213	-270	-301	-294	-251	-312	-517
Dividend Paid ⓘ	-54	-68	-68	-68	-68	-69	-70	-93	-137	-118
Others ⓘ	-47	452	-606	102	-20	41	-11	712	-279	378
Net Cash Flow ⓘ	141	163	488	166	-114	164	14	255	19	389

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	8.79	27.46	27.31	16.67	17.21	13.32	14.81	12.33	-0.97	-21.18
ROCE (%)	12.4	18.53	20.54	14.77	16.47	14.04	15.3	14.19	4.43	4.88
Asset Turnover Ratio	0.83	0.88	0.94	0.84	0.85	0.85	1.85	1.89	1.71	1.79
PAT to CFO Conversion(x)	2.31	0.46	0.59	2.05	1.43	1.79	1.17	1.12	N/A	N/A
Working Capital Days
Receivable Days	126	119	97	95	84	79	36	37	44	36
Inventory Days	59	68	74	84	79	75	32	31	32	32
Payable Days	354	310	263	222	227	219	220	192	186	190

Glenmark Pharmaceuticals Ltd Stock News

Glenmark Pharmaceuticals Ltd FAQs

What is the share price of Glenmark Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Glenmark Pharma on 25-Oct-2024 15:22 is ₹1,662.6.

What is the market cap of Glenmark Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 25-Oct-2024 15:22 the market cap of Glenmark Pharma stood at ₹46,949.1.

What is the P/E ratio of Glenmark Pharma?

The latest P/E ratio of Glenmark Pharma as of 25-Oct-2024 15:22 is 8.78.

What is the P/B ratio of Glenmark Pharma?

The latest P/B ratio of Glenmark Pharma as of 25-Oct-2024 15:22 is 2.00.

What is the 52-week high and low of Glenmark Pharma?

The 52-week high of Glenmark Pharma is ₹1,830.1 and the 52-week low is ₹702.0.

What is the TTM revenue of Glenmark Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glenmark Pharma is ₹7,849 ( Cr.) .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.

India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.

Business area of the company

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Awards

It was conferred with the Pharmaexcil Gold Award for New Chemical Entities 2015.
SCRIP crowned Glenmark as the ‘Best Pharma Company in Emerging markets’ and ‘Best Overall Pipline’ at SCRIP Awards 2011 in London.
Swiss Ambassador's award for Exceptional Innovation - 2012.
It received the Bombay Chamber of Commerce and Industry Civic Award 2014.
It was conferred with the prestigious Golden Peacock Management Award - 2015 for its Environment Sustainability initiatives at the Goa manufacturing facility.

Milestone

2010

Glenmark Pharmaceuticals has entered into a settlement and license agreement with Sepracor Inc to market generic Eszopiclone tablets.

2012

Forest Laboratories and Glenmark Sign Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions.

2014

Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitor.

2015

Glenmark announced the Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. In the same year, Glenmark received approval for generic Seretide in Russia.

2016

Glenmark launched ezetimibe, the first and only generic version of Zetia in the United States for the treatment of high cholesterol.

2019

Glenmark Pharmaceuticals and Mankind Pharmaceuticals have inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
Glenmark Pharmaceuticals’ partner -- Seqirus Pty (Seqirus) has received marketing approval for Ryaltris from the Therapeutic Goods Administration (TGA), Australia.

2020

Glenmark Pharmaceuticals has launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
Glenmark Pharmaceuticals has launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI).
Glenmark Pharmaceuticals has launched of a Single Inhaler Triple Therapy AIRZ-FF.
Glenmark Pharmaceuticals has entered into an agreement with Hindustan Unilever (HUL) for divestment of its VWash brand and other extensions.
Glenmark Pharmaceuticals’ Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma) for commercializing its novel nasal spray Ryaltris in the US.